A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Exclusion Criteria

• •Have known active CNS metastases and/or carcinomatous meningitis
• •Have any unresolved toxicities from prior therapy greater than NCI CTCAE Version 5.0 Grade 1 at the time of starting trial treatment, except for alopecia, hearing loss, peripheral neuropathy and ongoing endocrinopathies controlled on appropriate replacement therapy
• •Have significant cardiovascular disease defined as unstable angina or acute coronary syndrome, history of myocardial infarction, known left ventricular ejection fraction or heart failure, uncontrolled or symptomatic arrhythmias.
• •Have known active hepatitis B virus (HBV), hepatitis C virus (HCV) or untreated HIV infection
• •Have other active malignancy unless in remission with life expectancy greater than 2 years.
• •Have active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
• •Have history of non-infectious pneumonitis/interstitial lung disease that received steroids or has current clinically significant pneumonitis/interstitial lung disease